Work

Outcomes of patients (pts) with de novo metastatic hormone-sensitive prostate cancer (mHSPC) who progressed to metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TRUMPET registry.

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.16_suppl.e17085

Authors: Daniel H. Shevrin, James Thomas Symanowski, Neal D. Shore, Daniel W. Lin, David Russell, Pavol Kral, Yi Song, Nader N. El-Chaar, Lawrence Ivan Karsh

Institutions: Endeavor Health, Levine Cancer Institute, Carolina Urologic Research Center, University of Washington, Institute for Prostate Cancer Research, Pfizer (United States), Astellas Pharma (United States), The Urology Center of Colorado

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4379282194

Cites:

Cited by: 1

Related to: 10